[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 8 - Int J Mol Cell Med (Suppl 1) [In press] ::
Int J Mol Cell Med 2019, 8 - Int J Mol Cell Med (Suppl 1) [In press]: 0-0 Back to browse issues page
Liquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations
Fatemeh Khatami1, Bagher Larijani2, Shirzad Nasiri3, Seyed Mohammad Tavangar 4
1- Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
2- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
3- Departments of Surgery, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran.
4- Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; Departments of Pathology, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. , tavangar@ams.ac.ir
Abstract:   (429 Views)
In the blood of cancer patients, some nucleic acid fragments and tumor cells can be found that make it possible to trace tumor changes through a simple blood test called “liquid biopsy”. The main components of liquid biopsy are fragments of DNA and RNA shed by tumors into the bloodstream and circulate freely( ctDNAs and ctRNAs). tumor cells which are shed into the blood (circulating tumor cells or CTCs), and exosomes that have been investigated for non-invasive detection and monitoring of several tumors including thyroid cancer. Genetic and epigenetic alterations of a thyroid tumor can be a driver for tumor genesis or essential for tumor progression and invasion. Liquid biopsy can be real-time representative of such genetic and epigenetic alterations in order to trace tumors. In thyroid tumors, the circulating BRAF mutation is now taken into account for both thyroid cancer diagnosis and determination of the most effective treatment strategy. Several recent studies indicate the ctDNA methylation pattern of some iodine transporters and DNA methyltransferase as a diagnostic and prognostic biomarker in thyroid cancer as well. There is a big hope that the recent advances of genome sequencing together with liquid biopsy can be a game changer in oncology.
Keywords: Liquid biopsy, ctDNA, circulating tumor cells, exosomes, mutation, methylation
     
Type of Study: Review | Subject: Biomarkers (diagnosis & treatment)
Received: 2019/03/13 | Accepted: 2019/05/19 | Published: 2019/07/5
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Khatami F, Larijani B, Nasiri S, Tavangar S M. Liquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations. Int J Mol Cell Med. 2019; 8 (S1)
URL: http://ijmcmed.org/article-1-1038-en.html


Volume 8 - Int J Mol Cell Med (Suppl 1) [In press] Back to browse issues page
International Journal of Molecular and Cellular Medicine (IJMCM) International Journal of Molecular and Cellular Medicine (IJMCM)
Persian site map - English site map - Created in 0.05 seconds with 31 queries by YEKTAWEB 3937